as 11-14-2025 12:18pm EST
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
| Founded: | 1992 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | 255.5B | IPO Year: | 1993 |
| Target Price: | N/A | AVG Volume (30 days): | 4.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | Dividend Payout Frequency: | Semi-Annual | |
| EPS: | 6.02 | EPS Growth: | 45.02 |
| 52 Week Low/High: | $61.24 - $89.43 | Next Earning Date: | 11-06-2025 |
| Revenue: | $58,127,000,000 | Revenue Growth: | 13.52% |
| Revenue Growth (this year): | 10.78% | Revenue Growth (next year): | 6.03% |
AZN Breaking Stock News: Dive into AZN Ticker-Specific Updates for Smart Investing
Yahoo Finance
a day ago
MT Newswires
a day ago
Investor's Business Daily
2 days ago
Barrons.com
2 days ago
Zacks
2 days ago
Zacks
3 days ago
Investor's Business Daily
4 days ago
MT Newswires
4 days ago
The information presented on this page, "AZN AstraZeneca PLC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.